As part of the agreement, Idorsia will receive an upfront payment and retain marketing authorisations in each country.
Following local regulatory approval, the company will supply the finished product to Pharmalink at a pre-determined price. Pharmalink will handle sales, promotion, and distribution in the designated markets.
Quviviq is a dual orexin receptor ant...